On February 2, AbbVie announced its performance in the fourth quarter and full year of 2021, representing an annual revenue of USD 56.197 billion (+22.7%) and R&D investment of USD 7.084 billion (+8%).
From the business segments, in 2021, AbbVie represented a revenue in immune diseases of USD 25.284 billion (+14.1%), USD 7.228 billion (+8.7%) in neoplastic hematologic disorders, USD 5.927 billion (+69.5%) in nervous system diseases, USD 3.567 billion (+63.3%) in ophthalmic nursing, USD 5.233 billion in medical aesthetics, USD 796 million in women's health and USD 5.489 billion in other key products.
In terms of specific products, AbbVie has 13 products with sales volume exceeding USD 1 billion in 2021, among which Hu-mira has a sales volume exceeding USD 20 billion. It is expected to remain at the top of the global drug sales list in 2021. In addition, two other autoimmune drugs of AbbVie, Skyrizi (IL-23 inhibitor) and Rinvoq (JAK inhibitor), also performed well, with the sales volumes of USD 2.939 billion and USD 1.651 billion in 2021 respectively.
In 2021, both candidate drugs for autoimmune diseases have made new advanced. Skyrizi (risankizumab, 150mg) was approved by EMA in November 2021 as a single drug or combined with me-thotrex-ate (MTX) to treat adult active psoriatic arthritis (PsA) with insufficient response or intolerance to one or more disease-modifying antirheumatic drugs (DMARD). Moreover, the application of a new indication for the treatment of moderately to severely active Crohn's disease (CD) in patients (aged ≥ 16 years) with insufficient response, loss of response or intolerance to conventional or biological agents was accepted by EMA in December 2021. In the United States, FDA approved Skyrizi (risankizumab) of a single dose of 150mg injection for the treatment of moderate to severe plaque psoriasis in adults in April 2021.
Rinvoq was approved by EMA in January 2021 for the treatment of adult active psoriatic arthritis (PsA) with insufficient response or intolerance to one or more disease-modifying antirheumatic drugs (DMARD), and for the treatment of adults with active ankylosing spondylitis (AS) who have an inadequate response to conventional therapy. In August 2021, the drug was approved by EMA for the treatment of adults and adolescents aged 12 years and above with moderate to severe atopic dermatitis (AD) suitable for systematic treatment. In addition, in September 2021, Rinvoq was submitted to FDA and EMA for regulatory approval for the treatment of moderately to severely active ulcerative colitis (UC) in adults. It was approved by FDA in December 2021 for the treatment of adults with active psoriatic arthritis (PsA) who have an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
As the candidate products of Hu-mira, it is difficult for Skyrizi and Rinvoq to replicate the success of Hu-mira. Especially for Rinvoq, due to the safety data of to-faci-tinib showed the risk of heart attack, FDA required to add additional information about malignant tumor and the risk of thrombosis in the American label of Rinvoq, as well as the mortality and MACE (defined as cardiac death, myocardial infarction and stroke) risk in the black box warning and warning and prevention measures. However, AbbVie still expects a lot for the two products, which may generate a sales volume of USD 15 billion by 2025.
Both Im-bru-vica and Venclexta maintained steady growth in terms of neoplastic hematologic disorders. In 2021, clinical research of the combination of Im-bru-vica and Venclexta for the first-line treatment of CLL yielded positive results. Moreover, in September 2021, Im-bru-vica won a patent lawsuit in the United States Courthouse, preventing its generic drug from being sold until 2036.
In terms of the segment of nervous system diseases, the sales volume of Ubrelvy ...
(All Rights Reserved)